Green Cross Health (GXH) AGM Presentation summary
Event summary combining transcript, slides, and related documents.
AGM Presentation summary
15 May, 2026Key milestones and strategic initiatives
Achieved free prescriptions for all enrolled patients and rebranded the Living Rewards loyalty programme, now exceeding 2.03 million members.
Completed multiple acquisitions, expanding to 66 medical centres and over 423,000 enrolled patients.
Successfully refinanced group debt facilities and invested in technology, including pharmacy robots.
Significant refurbishments and rebranding efforts in medical centres to enhance patient care.
Financial performance overview
Group revenue rose 2% to $503.9m, driven by acquisitive growth in Medical and strong Pharmacy performance.
Operating profit fell 7% to $31.8m, impacted by labour cost pressures and reduced COVID-19 services.
Net profit after tax dropped 20% to $12.0m; EPS at 8.4 cps.
Final FY24 dividend of 2.0cps declared, following a special dividend of 28cps after a major divestment.
Divisional performance and growth
Pharmacy revenue increased 1% to $363.6m, with operating profit down 8% due to margin pressures.
Dispensed 36 million script items, representing over 40% of New Zealand's volume.
Medical revenue up 5% to $140.3m, with operating profit down 8% to $15.0m.
Continued growth in vaccination income and expansion of vaccine offerings.
Latest events from Green Cross Health
- Revenue hit $523.8m, net profit $16.0m, and a 2.75c dividend was declared.GXH
H2 202515 May 2026 - Revenue and profit growth driven by acquisitions, innovation, and expanded clinical services.GXH
AGM Presentation15 May 2026 - Revenue up 2%, profit down 20% as inflation and lower COVID-19 activity hit margins.GXH
H2 202415 May 2026 - Net profit and revenue rose, with medical services leading growth and a higher interim dividend declared.GXH
H1 202627 Nov 2025 - Revenue and profit rose as clinical services, digital innovation, and governance advanced.GXH
AGM 202516 Nov 2025 - Revenue, profit, and cash flow rose, with growth in both Pharmacy and Medical segments.GXH
H1 202513 Jun 2025